Aldeyra Therapeutics Files 2024 10-K

Ticker: ALDX · Form: 10-K · Filed: Feb 28, 2025 · CIK: 1341235

Sentiment: neutral

Topics: 10-K, annual-report, pharmaceuticals

TL;DR

Aldeyra's 2024 10-K is in. Check financials and biz ops.

AI Summary

Aldeyra Therapeutics, Inc. filed its 2024 10-K on February 28, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Neuron Systems Inc and Aldexa Therapeutics, Inc., is based in Lexington, MA. Key financial details and operational aspects for the fiscal year 2024 are presented in this filing.

Why It Matters

This filing provides a comprehensive overview of Aldeyra Therapeutics' financial health and business operations for the past fiscal year, crucial for investors and stakeholders to assess the company's performance and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Aldeyra Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Aldeyra Therapeutics, Inc.?

Aldeyra Therapeutics, Inc. is primarily involved in the pharmaceutical preparations industry, as indicated by its Standard Industrial Classification code [2834].

When was Aldeyra Therapeutics, Inc. previously known by other names?

The company was formerly known as Neuron Systems Inc until October 12, 2005, and then as Aldexa Therapeutics, Inc. until January 2, 2013.

Where is Aldeyra Therapeutics, Inc. located?

The company's business and mailing address is 131 Hartwell Avenue, Suite 320, Lexington, MA 02421.

What is the SEC file number for Aldeyra Therapeutics, Inc.'s 10-K filing?

The SEC file number for this filing is 001-36332.

What is the accession number for this 10-K filing?

The accession number for this filing is 0000950170-25-030102.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on February 28, 2025 regarding Aldeyra Therapeutics, Inc. (ALDX).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing